AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005067/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
提供机构：
Vivli
创建时间：
2019-11-27
